Previous Close | 10.77 |
Open | 10.75 |
Bid | 0.00 x 900 |
Ask | 0.00 x 1000 |
Day's Range | 10.54 - 11.25 |
52 Week Range | 6.08 - 11.93 |
Volume | |
Avg. Volume | 1,710,738 |
Market Cap | 902.494M |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.76 |
Earnings Date | Feb 20, 2024 - Feb 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.53 |
Subscribe to Yahoo Finance Plus to view Fair Value for EDIT
Key Insights Institutions' substantial holdings in Editas Medicine implies that they have significant influence over...
On Nov. 25, 2022, I mentioned three stocks to buy that could soar in 2023. At the time, those included Advanced Micro Devices (NASDAQ:AMD), which ran from $73 to $121.53; Apple (NASDAQ:AAPL), which ran from $146 to $191.45; and Nvidia (NASDAQ:NVDA), which ran from $152 to $504. Today, I was asked for a new list of stocks to buy that could double in the new year. So far, I like what I still see with artificial intelligence (AI), cryptocurrencies and gene editing. Advanced Micro Devices (AMD) Sour
Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics (NASDAQ:CRSP), a move that could set off a firestorm of interest in all things gene editing. All after a U.S. FDA advisory panel gave it the green light just days ago. While CRSP already ran from about $37.50 to $67.89, it could see higher highs as it nears its Dec. 8 PDUFA date with the U.S. FDA. Even